Biohaven Ltd. Common Shares
IPOClinical-stage Biopharmaceutical Company | Biohaven
Public · New Haven, United States · Founded 2013 · $493.6M raised
- Headquarters
- New Haven, Connecticut
- Employees
- 201–500
- Founded
- 2013
- Business Model
- B2B
- Website
- biohaven.com
- Total Funding
- $493.6M
- Last Round
- $375.0M Venture RoundAug 2020
- Rounds
- 4
- Type
- Public
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
About
Biohaven is a clinical-stage biopharmaceutical company advancing a portfolio of more than 10 drug candidates across 6 therapeutic areas including neurology, immunology, oncology, and cardiometabolic disease. Its proprietary platforms — MoDE extracellular protein degraders, Kv7 potassium channel activators, and myostatin inhibitors — target rare and common diseases with unmet needs. Lead programs include BHV-8000 for Parkinson's disease and Alzheimer's, opakalim (BHV-7000) for epilepsy, and taldefgrobep alfa for spinal muscular atrophy and obesity.
Summary
Biohaven Ltd. Common Shares is a Biotech company based in New Haven, United States, founded in 2013. It has raised $493.6M in total across 4 rounds, most recently a $375.0M Venture Round in Aug 2020. Investors include Oberland Capital, Sixth Street and Venrock.
Tech & App Stack
Funding & Exit History
Nov 2025
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Integrated biopharmaceutical solutions company
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/biohaven-ltd-common-shares"><img src="https://indexed.vc/api/badge/company/biohaven-ltd-common-shares" alt="Biohaven Ltd. Common Shares on Indexed.vc" width="260" height="76" /></a>